Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta‐analysis

@article{Wang2018Tadalafil5M,
  title={Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta‐analysis},
  author={Yilin Wang and Yiping Bao and Jie Liu and Lijun Duan and Yuanshan Cui},
  journal={LUTS: Lower Urinary Tract Symptoms},
  year={2018},
  volume={10}
}
We carried out a systematic review and meta‐analysis to assess tadalafil 5 mg once‐daily for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). 
Add‐on effects of tadalafil in tamsulosin‐treated patients with small benign prostatic enlargement: A randomized, placebo‐controlled, double‐blind, crossover study
TLDR
To assess the add‐on effects of tadalafil in patients with a relatively small benign prostatic enlargement treated with tamsulosin, a large number of patients with small BPEs are treated with this drug.
Erectile Dysfunction and Lower Urinary Tract Symptoms
TLDR
The role of phosphodiesterase inhibitors alone or in combination with alpha blockers to treat LUTS and ED, especially in younger patients, is strongly supported by high level of evidence.
Phosphodiesterase type 5 inhibitors in treatment of lower urinary tract dysfunctions
TLDR
The mechanisms of the therapeutic action of these drugs for various urinary tract dysfunctions are examined in detail, the leading of which is the improvement of blood circulation and the reduction of ischemia of the pelvic organs.
Impact of low‐dose tadalafil on adverse events after low‐dose‐rate brachytherapy for prostate cancer: A bi‐center randomized open‐label trial
  • T. Minagawa, T. Oguchi, O. Ishizuka
  • Medicine, Physics
    International journal of urology : official journal of the Japanese Urological Association
  • 2021
To study the efficacy of phosphodiesterase‐5 inhibitor tadalafil in attenuating adverse events after low‐dose‐rate brachytherapy for prostate cancer.
The safety and efficacy of PDE5-inhibitors-vardenafil on treating diabetes mellitus erectile dysfunction
TLDR
A systematic review and meta-analysis of the effectiveness, recurrence rate, and symptom scores of Diabetic mellitus erectile dysfunction using PDE5-inhibitors-vardenafil and related randomized controlled trials included in the China Resources Database is conducted.
Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?
TLDR
It is time to perform further long-term prospective randomized studies to further analyze the cardiovascular effects of PDE5Is as combination treatment with alpha blockers in the management of LUTS.
Is Early Surgical Treatment for Benign Prostatic Hyperplasia Preferable to Prolonged Medical Therapy: Pros and Cons
TLDR
Randomized clinical trials comparing the outcomes for prolonged medical therapy versus early surgical treatment could determine which approach is more beneficial in the long-term in context of the aging population.
Efficacy and safety of PDE5 inhibitors in the treatment of diabetes mellitus erectile dysfunction
TLDR
This study will provide a comprehensive assessment based on current evidence of PDE5 inhibitors for DMED, especially its impacts on International Index of Erectile Function, the sexual satisfaction of patients and their partners and safety.
Frequency of common complications during treatment of patients with benign prostate hyperplasia
Department of Urology, General Hospital Gradiška, Gradiška, the Republic of Srpska, Bosnia and Herzegovina Department of Surgery, University Clinical Centre of the Republic of Srpska, Banja Luka, the
...
...

References

SHOWING 1-10 OF 49 REFERENCES
Tadalafil 5 mg once‐daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double‐blind, placebo‐controlled trial carried out in Japan and Korea
TLDR
To gain further evidence on the efficacy, safety and tolerability of tadalafil 5 mg once‐daily in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, a large number of men were referred for treatment with this drug.
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo‐ and tamsulosin‐controlled 12‐week study in Asian men
To examine the efficacy and safety of tadalafil in Asian men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action
TLDR
This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition.
Tadalafil in the treatment of erectile dysfunction
TLDR
The pharmacokinetic and pharmacodynamic characteristics, efficacy, and safety of tadalafil, the preferred first-line treatment for erectile dysfunction, are discussed.
The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence
TLDR
The link between ED and LUTS has biologic plausibility given the four leading theories of how these diseases inter-relate and is supported by the consistent linear relationship of more severe LUTs with more severe ED.
A placebo‐controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK‐369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia
TLDR
Study Type – Therapy (RCT)’s level of evidence’1b, and “Level of Evidence 1b” indicate that RCTs are more likely to provide positive results than placebo-controlled trials.
The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society
The standardisation of terminology of lower urinary tract function: Report from the standardistation sub-committee of the International Continence Society.
...
...